Overview

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Status:
Completed

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to test the hypothesis that glycemic control, as measured by change in hemoglobin A1c (HbA1c) from baseline to endpoint, with exenatide is superior to that of placebo after 28 weeks of treatment in adolescent patients with type 2 diabetes who are naïve to antidiabetes agents, or patients who are being treated with metformin, an SU, or a combination of metformin and an SU

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

inVentiv Health Clinical
Quintiles, Inc.

Treatments:

Exenatide
Hypoglycemic Agents